Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations-Reference-Cited by-同舟云学术

Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations

Published:2020-09-25 Issue:2 Volume:185 Page:371-380
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Jiang Yi-Zhou,Ge Li-Ping,Jin Xi,Fan Lei,He Min,Liu Yin,Chen Li,Zuo Wen-Jia,Wu Jiong,Liu Guang-Yu,Di Gen-Hong,Wang Zhong-Hua,Yu Ke-Da,Shao Zhi-Ming^ORCID

Funder

National Natural Science Foundation of China

The Training Plan of Excellent Talents in the Shanghai Municipality Health System

The “Chen Guang” Project supported by the Shanghai Municipal Education Commission and Shanghai Education Development Foundation

The Shanghai Pujiang Program

The Training Plan of Excellent Talents of Fudan University Shanghai Cancer Center

The Shanghai Youth Excellent Academic Leader Program

The Municipal Project for Developing Emerging and Frontier Technology in Shanghai Hospitals

The Cooperation Project of Conquering Major Diseases in the Shanghai Municipality Health System

The Innovation Team of the Ministry of Education

The Shanghai Key Laboratory of Breast Cancer

Research Funding from Pfizer

the Shanghai Sailing Program

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-020-05940-8.pdf

Reference35 articles.

1. Curigliano G, Criscitiello C (2017) Maximizing the clinical benefit of anthracyclines in addition to taxanes in the adjuvant treatment of early breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 35(23):2600–2603. https://doi.org/10.1200/jco.2017.72.5960

2. Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kummel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A (2019) A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer—clinical results and biomarker analysis of GeparNuevo Study. Ann Oncol Off J Eur Soc Med Oncol 30:1279–1288. https://doi.org/10.1093/annonc/mdz158

3. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonzalez-Angulo AM, Mills GB, Pinto JA, Gomez HL, Arteaga CL (2012) Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18(7):1052–1059. https://doi.org/10.1038/nm.2795

4. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (Lond Engl) 384(9938):164–172. https://doi.org/10.1016/s0140-6736(13)62422-8

5. Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V (2016) Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol 2(4):508–516. https://doi.org/10.1001/jamaoncol.2015.4935

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficiency of simultaneous CNV-seq and whole-exome sequencing for testing fetal structural anomalies;Journal of Translational Medicine;2022-01-03